PRIG
GILD icon

Payden & Rygel Investment Group’s Gilead Sciences GILD Stock Holding History

Payden & Rygel Investment Group’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		$12K Sell
180
-2,500
-93% -$167K ﹤0.01% 121
2024
Q1 		$196K Buy
+2,680
New +$206K 0.01% 119
2023
Q3 		$201K Buy
+2,680
New +$206K 0.01% 119

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Payden & Rygel Investment Group's GILD Position: Q2 2024 in Review

Payden & Rygel Investment Group reduced its Gilead Sciences (GILD) stake by 93% in Q2 2024, selling an estimated $167K and leaving 180 shares worth $12K. The position accounts for ﹤0.01% of the portfolio, ranked #121.

Payden & Rygel Investment Group first reported a position in GILD in Q3 2023 and has held it in 3 quarters since. The position peaked at $201K in Q3 2023. 1,678 funds tracked by Wall St. Rank hold GILD as of Q2 2024.

  • Payden & Rygel Investment Group held 180 shares of Gilead Sciences worth $12K as of Q2 2024.
  • Payden & Rygel Investment Group sold 2,500 Gilead Sciences shares in Q2 2024, an estimated $167K.
  • Gilead Sciences made up ﹤0.01% of Payden & Rygel Investment Group's portfolio in Q2 2024, its #121 holding.
  • Payden & Rygel Investment Group first reported a position in Gilead Sciences in Q3 2023 and has held it in 3 quarters since.
  • Payden & Rygel Investment Group's Gilead Sciences position peaked at $201K in Q3 2023.
  • 1,678 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2024.

Based on Payden & Rygel Investment Group's 13F filing for Q2 2024, filed 12 Aug 2024.